Stay updated with breaking news from Eric Sciorilli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Prior Approval Supplement for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription Drug User Fee Act goal date of October 30, 2023 by the U.S. Food and Drug Administration ... -Today at 08:02 am- MarketScreener
Prescription Drug User Fee Act goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12,... | June 12, 2023
FLORHAM PARK, N.J., June 01, 2023 -- Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced... | June 1, 2023
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and...
Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year endIf approved, vonoprazan would be the first innovative acid... | May 23, 2023